NCT05539157View on ClinicalTrials.gov

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

May 31, 2024

Conditions
Cutaneous TumorMalignant Solid Tumor
Interventions
DRUG

JCXH-211

JCXH-211 administered once every 28 days

Trial Locations (1)

77030

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Immorna Biotherapeutics, Inc.

INDUSTRY

NCT05539157 - Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors | Biotech Hunter | Biotech Hunter